DUBLIN, Ireland, July 15, 2010 Shire plc (LSE:SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, willannounce second quarter 2010 earnings on Wednesday August 4, 2010.
Live conference call for investors:
Angus Russell, Chief Executive Officer and Graham Hetherington, ChiefFinancial Officer will host the investor and analyst conference call at 14:00BST/9:00 EDT.
A replay of the presentation will be available for two weeks by phone andby webcast for one year. Details can be found on our Investor Relationswebsite http://www.shire.com/shireplc/en/investors.
Notes to editors
Shire's strategic goal is to become the leading specialtybiopharmaceutical company that focuses on meeting the needs of the specialistphysician. Shire focuses its business on attention deficit hyperactivitydisorder (ADHD), human genetic therapies (HGT) and gastrointestinal (GI)diseases as well as opportunities in other therapeutic areas to the extentthey arise through acquisitions. Shire's in-licensing, merger and acquisitionefforts are focused on products in specialist markets with strongintellectual property protection and global rights. Shire believes that acarefully selected and balanced portfolio of products with strategicallyaligned and relatively small-scale sales forces will deliver strong results.
For further information on Shire, please visit the Company's website:http://www.shire.com.Results press release will be issued at: 12:00 BST / 07:00 EDT Investor conference call time: 14:00 BST / 09:00 EDT
SOURCE Shire plc